… the first human papillomavirus (HPV) vaccine was introduced. These vaccines have received
… issues associated with HPV vaccine uptake and acceptability, given the changing HPV …

… cancer and more than 85% of the 265,653 deaths occurred in developing countries (Fig. 1).
… papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination …

… Cervarix® product information: human papillomavirus vaccine type 16 and 18 (Recombinant
AS04 adjuvanted), 2007. Boronia, Victoria, Australia, 2007 (http://www.gsk.com.au/…

… While developed countries have significantly reduced cervical cancer through screening, …
Human papillomavirus vaccine demonstration project in Cameroon 2010–2012. * The column …

… HPV vaccine in each country and total samples in each country with an associated 95%
confidence interval (CI). The secondary outcomes were the types of vaccines used, vaccination …

… About 80% of cervical cancers occur in less-developed countries, primarily because they
lack sufficient resources for high-quality cervical cancer screening programs that detect cervical …

… Initial commercial development of HPV vaccines was under… developed a bivalent vaccine
(Cervarix), composed of HPV-16 and HPV-18 VLPs. Merck developed a quadrivalent vaccine (…

… vaccine, efficacy of a new vaccine similar to a licensed vaccine or efficacy of a novel vaccine
developed … A polyvalent vaccine has been developed by including VLPs for additional HPV …

… efficient HPV vaccine introduction in developing countries will provide a valuable opportunity
for AIDS vaccine researchers and advocates to learn from the HPV vaccine experience in …

… for developing countries preventive vaccination may be the only possibility to significantly
reduce cervical cancer incidence. Also in the developed countries … by HPV vaccination (for a …